BiotechTube

Shenfu Injection + 5% Glucose Injection

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
82
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Myocardial Infarction

Conditions

Myocardial Infarction

Trial Timeline

Apr 1, 2016 โ†’ Feb 1, 2018

NCT ID
NCT02709798

About Shenfu Injection + 5% Glucose Injection

Shenfu Injection + 5% Glucose Injection is a approved stage product being developed by China Resources Pharmaceutical Group for Myocardial Infarction. The current trial status is completed. This product is registered under clinical trial identifier NCT02709798. Target conditions include Myocardial Infarction.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT02709798ApprovedCompleted

Competing Products

20 competing products in Myocardial Infarction

See all competitors
ProductCompanyStageHype Score
Butylphthalide + Butylphthalide placeboCSPC Pharmaceutical Group LimitedPhase 3
76
AbciximabEli LillyApproved
85
Prasugrel + ClopidogrelDaiichi SankyoPhase 3
77
Regadenoson + gadofoveset trisodiumAstellas PharmaPhase 2
52
Half-dose of the Tc99-m sestamibi (Cardiolite)Astellas PharmaPre-clinical
23
No interventionAstellas PharmaPre-clinical
23
Empagliflozin + PlaceboEli LillyPhase 3
77
Abciximab + Abciximab placeboEli LillyPhase 3
77
Intracoronary infusion of enriched bone marrow-derived progenitor cells + Placebo medium supplemented with autologous serumEli LillyPhase 3
77
AbciximabEli LillyApproved
85
abciximab placebo; reteplase placebo, abciximab, abciximab + Abciximab; reteplase; abciximab placebo; abciximab + abciximab; reteplase placebo; abciximab placebo; abciximab + abciximab placebo; reteplase placebo, abciximab, abciximab + abciximab; reteplase placebo; abciximab placebo; abciximab + Abciximab; reteplase; abciximab placebo; abciximabEli LillyPhase 3
77
fibrinolytic therapy or combination reduced fibrinolytic therapyEli LillyPhase 3
77
abciximabEli LillyApproved
85
tenecteplase + enoxaparin + clopidogrelEli LillyPhase 2/3
65
Thrombolytic therapyEli LillyPre-clinical
23
TicagrelorAstraZenecaPre-clinical
23
TicagrelorAstraZenecaPhase 2
52
Dual-antiplatelet therapy + Dual-antiplatelet therapyAstraZenecaPre-clinical
23
Metoprolol- Toprol XL + Metoprolol- LopressorAstraZenecaPhase 1
33
Ticagrelor orodispersible tablets + Ticagrelor standard tabletsAstraZenecaPhase 3
77

Other Products from China Resources Pharmaceutical Group

Shenfu Zhusheye + 5% glucose injectionApproved
82
Jinfukang oral liquid + Platinum-based doublet chemotherapyApproved
82
Yuxuebi tablet + Placebo tabletApproved
82
Mifepristone tabletsApproved
82
Qizhi weitong granules(High๏ผ‰ + Qizhi weitong granules(Low๏ผ‰ + PlaceboPhase 2
49